Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 11337 - 11344 of 12011 results

J-1 Interns and Trainees: What happened at Wyndham should stay at Wyndham
August 6, 2012| Blog| Viewpoint

Theft of Employee Data from Third-Party Vendor Exposes Employer and Vendor to Privacy Class Action
August 2, 2012| Blog| Viewpoint

Cybersecurity Act of 2012 Fails in Senate -- " A moment of disappointment..."
August 2, 2012| Blog| Viewpoint

Sunbeam Decision Gives a Ray of Hope to Trademark Licensees
July 31, 2012| Blog| Viewpoint

D.C. Circuit Rejects Length of Purdue Executives' Exclusion but Remands for Reconsideration
July 29, 2012| Blog| Viewpoint

Morbid Obesity as a Covered Disability under the ADA
July 27, 2012| Blog| Viewpoint

Law & Order PEPU: California's new Privacy Enforcement and Protection Unit
July 27, 2012| Blog| Viewpoint

Public-Private Partnership to Fight Fraud Formed
July 27, 2012| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
